Molecular Partners AG ADR
Price & Volume
Stats
See more52W Range | $3.32-$12.70 |
Market Cap | $160.6M |
Shares Short | 29,825 |
Financials
See moreRevenue (12 Mos) | $7.8M |
Revenue Growth (YoY) | 273.7% |
Gross Profit (12 Mos) | $138.8M |
Diluted EPS | -$2.07 |
News
See moreYahoo Finance • 11 months ago
Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting
Yahoo Finance • 11 months ago
Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition
Yahoo Finance • 11 months ago
Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin Portfolio
Yahoo Finance • last year
Molecular Partners Reports H1 2023 Corporate Highlights and Financials
About
CEO | Dr. Patrick Amstutz Ph.D. |
Address | Wagistrasse 14, Schlieren, Switzerland, 8952 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 161 |
